Epiguajadial B exhibits significant potential in pharmaceutical research due to its pronounced anti-inflammatory and cytotoxic properties. It has been investigated for its ability to inhibit specific cancer cell lines, showing promise in early-stage oncology studies. Its mechanism involves interference with cellular signaling pathways associated with tumor growth and inflammation. Additionally, Epiguajadial B serves as a lead compound in the development of novel therapeutics targeting chronic inflammatory diseases and certain malignancies. Ongoing research focuses on optimizing its bioavailability and evaluating its efficacy in preclinical models.